Abstract
Background: Antithrombotic therapy in acute coronary syndrome (ACS) patients with concurrent atrial fibrillation (AF) remains a controversial topic. The evidence on which current international guidelines are based is of low quality, and consensus opinion is lacking. Given this, this study sought to define the current practice of prescribing across Australia and New Zealand in this cohort of patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
